A Mab A Case Study In Bioprocess Development ^hot^ «UHD»

The A-Mab case study, developed by the CMC Biotech Working Group, serves as a foundational guide for applying Quality by Design (QbD) principles to monoclonal antibody production. It outlines crucial strategies for defining Target Product Profiles and establishing design spaces in upstream and downstream processing to ensure product quality. Read the full case study at International Society for Pharmaceutical Engineering (ISPE) A–Mab: A Case Study in Bioprocess Development - ISPE

From this case study on Mab-X, the bioprocess development community can extract four universal lessons: A Mab A Case Study In Bioprocess Development

This case study demonstrates that a modern mAb process is not developed linearly. By integrating upstream media chemistry (clone #47B + metal modulation) with downstream flocculation and high-resilience Protein A capture, the team transformed a problematic, aggregate-prone mAb (initial yield <1.5 g/L recoverable) into a robust 6.1 g/L titer process with a 71% final recovery. The drug product met all Phase I release specifications for purity, potency, and safety. The A-Mab case study, developed by the CMC

The is a landmark industry document developed by the CMC Biotech Working Group to demonstrate the practical application of Quality by Design (QbD) principles to the development and manufacturing of monoclonal antibodies (mAbs) . Unlike traditional "test-to-quality" approaches, this study illustrates how to "build quality into" a product through deep process understanding and risk management. 1. Core Concept: Quality by Design (QbD) By integrating upstream media chemistry (clone #47B +